IL-31RA Inhibitors & Biosimilars
1 drugsAbout IL-31RA
Interleukin-31 receptor subunit alpha (IL-31RA) is a component of the IL-31 receptor, which also contains OSMRβ. The receptor is expressed on immune cells and sensory neurons, and its activation by IL-31 triggers inflammation and pruritus.
IL-31RA is a therapeutic target for immunological disorders, but there is currently no genetic evidence directly linking it to specific diseases. Targeting IL-31RA holds promise for treating conditions with excessive inflammation and itch.
IL-31RA is targeted by one approved drug, NEMLUVIO, a biologic. GALDERMA LABS LP is the sole company with an approved drug for this target, indicated for immunology.
Top IL-31RA Drugs
GALDERMA LABS LP is the only company with an approved drug targeting IL-31RA.
The lack of competition presents an opportunity, but also highlights potential market entry barriers.
IL-31RA Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IL-31RA, using biologic (other) modality.
Explore small molecule or alternative modalities to differentiate from existing therapies.
IL-31RA Clinical Trials 25 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IL-31RA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 13 | 8 | 0 | 5 | 100% |
| Phase 3 | 9 | 6 | 1 | 2 | 86% |
| Phase 4 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IL-31RA Drug Approval Timeline (2024 - 2024)
The first and most recent drug approval for IL-31RA was NEMLUVIO in 2024.
The recent approval suggests growing interest, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IL-31RA. A trial counts if an approved drug acting on IL-31RA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.